2Flo Ventures

Vivacelle Bio Announces Early Results of its Phase IIa Clinical Trial of VBI-S for Improving Hypovolemia Due to Sepsis

December 15, 2022

#2FloEquityNews: There is promising news in the fight against sepsis— a life-threatening complication of an infection that disproportionately impacts people of color.

The 2Flo portfolio company Vivacelle Bio has reached the halfway point of the Phase IIa clinical trial investigating the potential of its nanoparticle technology, VBI-S, to treat hypovolemia due to septic shock caused by bacterial infections. Early results suggest the technology is effective in raising blood pressure and improving oxygenation, even in late stages of septic shock.  In addition, clinically significant improvement in lung, kidney, and liver function was observed.

Why it matters: 

  • Sepsis contributes to over 1 in 3 hospital deaths.

  • 73% of COVID-19 deaths are due to sepsis, septic shock or sepsis-related organ failure.

  • Similar to COVID-19, people of color face higher rates of sepsis, leading to significantly increased risk of morbidity and mortality among these patients.  

This would be an invaluable tool in the ongoing fight against those bacterial infections that lead to septic shock, as well as for COVID-19 patients co-infected with a bacterial infection, also resulting in septic shock. Additionally, VBI-S has been successfully deployed as a compassionate-use drug to treat hypovolemia in COVID-19 patients.

Vivacelle Bio’s nanoparticle technology was invented by Dr. Cuthbert Simpkins, a Harvard-trained trauma surgeon and former Naval Officer. This latest research is being funded by a $5.3 million grant from the U.S. Navy.

As a Black-founded company working to address critical medical needs, Vivacelle Bio embodies our mission at 2Flo Ventures to close gaps in health outcomes for systemically disinvested communities. Thank you to Dr. Simpkins and the entire Vivacelle Bio team! 

Read Vivacelle’s press release here: https://www.businesswire.com/news/home/20221020005031/en/Vivacelle-Bio-Announces-Early-Results-of-its-Phase-IIa-Clinical-Trial-of-VBI-S-for-Improving-Hypovolemia-Due-to-Sepsis.

#Sepsis #COVID19 #healthequity #equitableinnovation #Blackleaders #venturecapital #startup #Chicago

Location & Contact

222 W Merchandise Mart Plaza | Suite 1230 | Chicago, IL 60654


2Flo Ventures